Drug metabolism in drug discovery and development

被引:216
作者
Zhang, Zhoupeng [1 ]
Tang, Wei [2 ]
机构
[1] Merck Sharp & Dohme Corp, Dept Pharmacokinet Pharmacodynam & Drug Metab, West Point, PA 19486 USA
[2] Shanghai ChemPartners, Shanghai 201203, Peoples R China
关键词
Bioactivation; Drug discovery and development; Drug metabolism; Metabolite; Pharmacokinetics; Pharmacodynamics; Safety; Toxicity; IN-VITRO BIOACTIVATION; LIVER-MICROSOMES; N-DEMETHYLATION; IDENTIFICATION; CYTOCHROME-P450; LIPOPHILICITY; ADDUCTS; PHARMACOKINETICS; AMITRIPTYLINE; PERSPECTIVE;
D O I
10.1016/j.apsb.2018.04.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug metabolism as a discipline plays an important role in drug discovery and development and the effects of drug metabolism on pharmacokinetics (PK), pharmacodynamics (PD), and safety should be carefully considered. This communication provides an overview of common strategies in the area of drug metabolism for improving PK/PD and safety profiles of drug candidates; these include, but are not limited to, collaboration with medicinal chemists on structure-activity relationships (SAR) to overcome high clearance, using deuterium replacement to further optimize a lead, prodrug approaches to circumvent formulation and delivery difficulties, and addressing issues such as species differences in metabolism, drug-drug interactions (DDI) and formation of reactive metabolites. (C) 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
引用
收藏
页码:721 / 732
页数:12
相关论文
共 48 条
  • [1] Auspex Pharmaceuticals Inc, AUSP ANN POS TOPL RE
  • [2] Bouska JJ, 1997, DRUG METAB DISPOS, V25, P1032
  • [3] Braeckman RA, 1989, J Clin Pharmacol, V29, pA22
  • [4] Tenoflovir disoproxil fumarate
    Antoniou, T
    [J]. DRUGS, 2003, 63 (15) : 1609 - 1609
  • [5] STRUCTURE OF CYTOCHROME P450ERYF INVOLVED IN ERYTHROMYCIN BIOSYNTHESIS
    CUPPVICKERY, JR
    POULOS, TL
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (02): : 144 - 153
  • [6] Substrate docking algorithms and prediction of the substrate specificity of cytochrome P450(cam) and its L244A mutant
    DeVoss, JJ
    Sibbesen, O
    Zhang, ZP
    deMontellano, PRO
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (24) : 5489 - 5498
  • [7] The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant
    Dierks, EA
    Zhang, ZP
    Johnson, EF
    de Montellano, PRO
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) : 23055 - 23061
  • [8] Innovation in the pharmaceutical industry: New estimates of R&D costs
    DiMasi, Joseph A.
    Grabowski, Henry G.
    Hansen, Ronald W.
    [J]. JOURNAL OF HEALTH ECONOMICS, 2016, 47 : 20 - 33
  • [9] ROLE OF SUBSTRATE LIPOPHILICITY ON THE N-DEMETHYLATION AND TYPE-I BINDING OF 3-O-ALKYLMORPHINE ANALOGS
    DUQUETTE, PH
    ERICKSON, RR
    HOLTZMAN, JL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (10) : 1343 - 1348
  • [10] Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development
    Evans, DC
    Watt, AP
    Nicoll-Griffith, DA
    Baillie, TA
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (01) : 3 - 16